Search
Iterum Therapeutics PLC
ITRMAdd to Watchlist
0.030USD
0.0000.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.87MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-03-31The current earnings forecast score of Iterum Therapeutics PLC is 8.00, ranking 164 out of 391 in the Biotechnology & Medical Research industry. The average price target is 5.50, with a high of 9.00 and a low of 2.00.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
9.000
Target Price
+25180.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Iterum Therapeutics PLC
ITRM
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Iterum Therapeutics PLC's price target?
Analysts forecast that Iterum Therapeutics PLC's price target is USD 5.50, with the highest forecast at USD 9.00 and the lowest forecast at USD 2.00.
How have Iterum Therapeutics PLCITRM's recent earnings per share performed?
The market expectation was USD -0.20, while Iterum Therapeutics PLCITRM's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.20.
What is the analyst rating for Iterum Therapeutics PLC?
Based on the ratings of Iterum Therapeutics PLC's stock from 1 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
